["[Tab] Consolidated Balance Sheets from Eli Lilly and Company\n\n[Time]: December 31, 2023 [SEP]\n[row 0]: Current Assets [SEP]\n[row 1]: Cash and cash equivalents (Note 7) | $2,818.6 [SEP]\n[row 2]: Short-term investments (Note 7) | $109.1 [SEP]\n[row 3]: Accounts receivable, net of allowances of $14.8 | $9,905.5 [SEP]\n[row 4]: Other receivables | $2,245.7 [SEP]\n[row 5]: Inventories (Note 6) | $5,772.8 [SEP]\n[row 6]: Prepaid expenses | $5,540.8 [SEP]\n[row 7]: Other current assets | $149.5 [SEP]\n[row 8]: Total current assets | $25,727.0 [SEP]\n[row 9]: Investments (Note 7) | $3,052.2 [SEP]\n[row 10]: Goodwill (Note 8) | $4,939.7 [SEP]\n[row 11]: Other intangibles, net (Note 14) | $6,096.0 [SEP]\n[row 12]: Deferred tax assets (Note 14) | $5,477.3 [SEP]\n[row 13]: Property and equipment, net (Note 9) | $12,913.6 [SEP]\n[row 14]: Other noncurrent assets | $4,989.9 [SEP]\n[row 15]: Total assets | $64,006.3 [SEP]\n\n[row 16]: Current Liabilities [SEP]\n[row 17]: Short-term borrowings and current maturities of long-term debt (Note 11) | $6,904.5 [SEP]\n[row 18]: Accounts payable | $2,598.8 [SEP]\n[row 19]: Employee compensation | $1,650.4 [SEP]\n[row 20]: Sales rebates and discounts | $11,689.0 [SEP]\n[row 21]: Dividends payable | $1,169.0 [SEP]\n[row 22]: Other current liabilities | $3,281.3 [SEP]\n[row 23]: Total current liabilities | $27,293.2 [SEP]\n\n[row 24]: Noncurrent Liabilities [SEP]\n[row 25]: Long-term debt (Note 11) | $18,320.8 [SEP]\n[row 26]: Accrued retirement benefits (Note 15) | $1,438.2 [SEP]\n[row 27]: Long-term income taxes payable (Note 14) | $3,849.2 [SEP]\n[row 28]: Other noncurrent liabilities | $2,240.0 [SEP]\n[row 29]: Total noncurrent liabilities | $25,849.4 [SEP]\n\n[row 30]: Commitments and Contingencies (Note 16) [SEP]\n[row 31]: Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) [SEP]\n[row 32]: Common stock\u2014no par value [SEP]\n Authorized shares [SEP]\n Issued shares: 949,781 (2023) and 950,632 (2022): 3,200,000| $593.6 [SEP]\n[row 33]: Additional paid-in capital | $7,250.6 [SEP]\n[row 34]: Retained earnings | $10,312.3 [SEP]\n[row 35]: Employee benefit trust | $(3,013.3) [SEP]\n[row 36]: Accumulated other comprehensive loss (Note 17) | $(4,327.0) [SEP]\n[row 37]: Cost of common stock in treasury | $(44.2) [SEP]\n[row 38]: Total Eli Lilly and Company shareholders' equity | $10,771.9 [SEP]\n[row 39]: Noncontrolling interests | $91.8 [SEP]\n[row 40]: Total equity | $10863.7 [SEP]\n[row 41]: Total liabilities and equity | $64,006.3 [SEP]\n\n[Time]: December 31, 2022 [SEP]\n[row 0]: Current Assets [SEP]\n[row 1]: Cash and cash equivalents (Note 7) | $2,067.0 [SEP]\n[row 2]: Short-term investments (Note 7) | $144.8 [SEP]\n[row 3]: Accounts receivable, net of allowances of $16.0 | $6,896.0 [SEP]\n[row 4]: Other receivables | $1,662.9 [SEP]\n[row 5]: Inventories (Note 6) | $4,309.7 [SEP]\n[row 6]: Prepaid expenses | $2,946.8 [SEP]\n[row 7]: Other current assets | $7.3 [SEP]\n[row 8]: Total current assets | $18,034.5 [SEP]\n[row 9]: Investments (Note 7) | $2,901.8 [SEP]\n[row 10]: Goodwill (Note 8) | $4,073.0 [SEP]\n[row 11]: Other intangibles, net (Note 14) | $7,206.6 [SEP]\n[row 12]: Deferred tax assets (Note 14) | $2,792.9 [SEP]\n[row 13]: Property and equipment, net (Note 9) | $10,144.0 [SEP]\n[row 14]: Other noncurrent assets | $4,337.0 [SEP]\n[row 15]: Total assets | $49,489.8 [SEP]\n\n[row 16]: Current Liabilities [SEP]\n[row 17]: Short-term borrowings and current maturities of long-term debt (Note 11) | $1,501.1 [SEP]\n[row 18]: Accounts payable | $1,930.6 [SEP]\n[row 19]: Employee compensation | $1,059.8 [SEP]\n[row 20]: Sales rebates and discounts | $8,784.1 [SEP]\n[row 21]: Dividends payable | $1,017.2 [SEP]\n[row 22]: Other current liabilities | $2,845.4 [SEP]\n[row 23]: Total current liabilities | $17,138.2 [SEP]\n\n[row 24]: Noncurrent Liabilities [SEP]\n[row 25]: Long-term debt (Note 11) | $14,737.5 [SEP]\n[row 26]: Accrued retirement benefits (Note 15) | $1,305.1 [SEP]\n[row 27]: Long-term income taxes payable (Note 14) | $3,709.6 [SEP]\n[row 28]: Other noncurrent liabilities | $1,824.0 [SEP]\n[row 29]: Total noncurrent liabilities | $21,576.2 [SEP]\n\n[row 30]: Commitments and Contingencies (Note 16) [SEP]\n[row 31]: Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) [SEP]\n[row 32]: Common stock\u2014no par value [SEP]\n Authorized shares [SEP]\n Issued shares: 949,781 (2023) and 950,632 (2022): 3,200,000| $594.1 [SEP]\n[row 33]: Additional paid-in capital | $6921.4 [SEP]\n[row 34]: Retained earnings | $10,042.6 [SEP]\n[row 35]: Employee benefit trust | $(3,013.3) [SEP]\n[row 36]: Accumulated other comprehensive loss (Note 17) | $(3,844.6) [SEP]\n[row 37]: Cost of common stock in treasury | $(50.5) [SEP]\n[row 38]: Total Eli Lilly and Company shareholders' equity | $10,649.8 [SEP]\n[row 39]: Noncontrolling interests | $125.6 [SEP]\n[row 40]: Total equity | $10775.4 [SEP]\n[row 41]: Total liabilities and equity | $49489.8 [SEP]\n\n[Time]: December 31, 2022 [SEP]"]